GeoPharma, Inc. (GORX) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 31 PAGES: 28

More Info
									            GeoPharma, Inc. (GORX) - Financial and Strategic Analysis Review

       Reference Code: GDPH56877FSA                                                                                      Publication Date: SEP 2010

       6950 Bryan Dairy Road           Phone            +1 727 5448866                               Revenue           22 (million USD)
       Largo, FL                        Fax             +1 727 5444386                               Net Profit        -26.06 (million USD)
       33777                            Website         www.geopharmainc.com                         Employees         271
       United States                    Exchange        GORX [NASDAQ]                                Industry          Pharmaceuticals & Healthcare

      Company Overview
       GeoPharma, Inc. (GeoPharma) is a Bio-Pharma company operating in diversified businesses. It is engaged in the manufacturing,
       packaging and distribution of private label dietary supplements, health and beauty products and generic drugs. It sells its
       products to companies worldwide through its subsidiary companies network. The company is headquartered in Largo, Florida. In
       March 2009, the company discontinued its distribution business segment. During Janaury 2009, GeoPharma entered into an
       agreement with Trident Biotech, Inc. for selling its majority stake in Ovarian Cancer business to focus in its core business.

      Key Executives                                                                SWOT Analysis
                    Name                                  Title                     GeoPharma, Inc., SWOT Analysis
      Mihir K. Taneja                      Chief Executive Officer                  Strengths                 Weaknesses

      Kotha S. Sekharam, Ph.D.             Director
                                                                                    Sturdy Research and                 Discontinuation of Distribution
      Carol Dore-Falcone                   Chief Financial Officer                  Development Activities              Segment
      Dr. Rafick Henein                    Director
                                                                                    Trademarks and Intellectual         Limited Liquidity Position
      William L. LaGamba                   Director                                 Property
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData

      Share Data                                                                    Opportunities                       Threats
      GeoPharma, Inc.
       Share Price (USD) as on 08-Sep-2010                               0.10       Expansion into Emerging             Highly Competitive US
                                                                                    Markets                             Generic Drug Market
       EPS (USD)                                                         -0.65

       Market Cap (million USD)                                                 1   Changing Demographics               Counterfeit Drugs
       Enterprise Value (million USD)                                       19

       Shares Outstanding (million)                                         23
       Source: Annual Report, Company Website, Primary and Secondary Research       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData                                                                   GlobalData


      Financial Performance                                                         Recent Developments
                                                                                    Aug 05, 2010        GeoPharma Completes              Recapitalization
                                                                                                        And Restructuring
                                                                                    Jun 30, 2010        The NASDAQ Stock Market To Delist
                                                                                                        Securities Of GeoPharma
                                                                                    Mar 02, 2010        GeoPharma Gets FDA Aprroval                    For
                                                                                                        Cephalosporin Plant In Florida
                                                                                    Mar 02, 2010        GeoPharma Announces Acceptability Of
                                                                                                        Largo Cephalosporin Plant
                                                                                    Sep 08, 2009        GeoPharma        Reports        Settlement      Of
                                                                                                        Litigation With CPG
       Source: Annual Report, Company Website, Primary and Secondary Research       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData                                                                   GlobalData




GeoPharma, Inc. (GORX) - Financial and Strategic Analysis Review                                                                 Reference Code: GDPH56877FSA

Source : www.globalmarketsandcompanies.com                                                                                                                   Page 1
      Table of Contents
      Table of Contents........................................................................................................................................................................................................... 2
      List of Tables .................................................................................................................................................................................................................. 3
      List of Figures................................................................................................................................................................................................................. 3
      Section 1 - About the Company ..................................................................................................................................................................................... 4
      GeoPharma, Inc. - Key Facts......................................................................................................................................................................................... 4
      GeoPharma, Inc. - Key Employees................................................................................................................................................................................ 5
      GeoPharma, Inc. - Key Employee Biographies.............................................................................................................................................................. 6
      GeoPharma, Inc. - Major Products and Services........................................................................................................................................................... 7
      GeoPharma, Inc. - History.............................................................................................................................................................................................. 8
      GeoPharma, Inc. - Company Statement ........................................................................................................................................................................ 9
      GeoPharma, Inc. - Locations And Subsidiaries ........................................................................................................................................................... 10
            Head Office............................................................................................................................................................................................................ 10
            Other Locations & Subsidiaries ............................................................................................................................................................................. 10
      Section 2 – Company Analysis .................................................................................................................................................................................... 11
      GeoPharma, Inc. - Business Description ..................................................................................................................................................................... 11
      GeoPharma, Inc. - SWOT Analysis.............................................................................................................................................................................. 12
            SWOT Analysis - Overview ................................................................................................................................................................................... 12
            GeoPharma, Inc. - Strengths ................................................................................................................................................................................. 12
                  Strength - Sturdy Research and Development Activities ................................................................................................................................ 12
                  Strength - Trademarks and Intellectual Property ............................................................................................................................................ 12
                  Strength - Expansion of Agreement ................................................................................................................................................................ 12
            GeoPharma, Inc. - Weaknesses............................................................................................................................................................................ 12
                  Weakness - Discontinuation of Distribution Segment ..................................................................................................................................... 12
                  Weakness - Limited Liquidity Position............................................................................................................................................................. 13
                  Weakness - Declining Market Share in Sector................................................................................................................................................ 13
            GeoPharma, Inc. - Opportunities ........................................................................................................................................................................... 13
                  Opportunity - Expansion into Emerging Markets............................................................................................................................................
								
To top